JP2015512246A - 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法 - Google Patents

細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法 Download PDF

Info

Publication number
JP2015512246A
JP2015512246A JP2015500675A JP2015500675A JP2015512246A JP 2015512246 A JP2015512246 A JP 2015512246A JP 2015500675 A JP2015500675 A JP 2015500675A JP 2015500675 A JP2015500675 A JP 2015500675A JP 2015512246 A JP2015512246 A JP 2015512246A
Authority
JP
Japan
Prior art keywords
polypeptide
domain
protein
surf
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015500675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512246A5 (enExample
Inventor
エリック エム． ボーガン，
エリック エム． ボーガン，
アレックス フランズソフ，
アレックス フランズソフ，
ジョン エドワーズ，
ジョン エドワーズ，
アン ドゥウィット，
アン ドゥウィット，
Original Assignee
パーミオン バイオロジクス， インコーポレイテッド
パーミオン バイオロジクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーミオン バイオロジクス， インコーポレイテッド, パーミオン バイオロジクス， インコーポレイテッド filed Critical パーミオン バイオロジクス， インコーポレイテッド
Publication of JP2015512246A publication Critical patent/JP2015512246A/ja
Publication of JP2015512246A5 publication Critical patent/JP2015512246A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015500675A 2012-03-15 2013-03-15 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法 Pending JP2015512246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611493P 2012-03-15 2012-03-15
US61/611,493 2012-03-15
PCT/US2013/032686 WO2013138795A1 (en) 2012-03-15 2013-03-15 Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use

Publications (2)

Publication Number Publication Date
JP2015512246A true JP2015512246A (ja) 2015-04-27
JP2015512246A5 JP2015512246A5 (enExample) 2016-05-12

Family

ID=49161881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015500675A Pending JP2015512246A (ja) 2012-03-15 2013-03-15 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法

Country Status (6)

Country Link
US (1) US20150266939A1 (enExample)
EP (1) EP2825561A4 (enExample)
JP (1) JP2015512246A (enExample)
AU (1) AU2013231851A1 (enExample)
CA (1) CA2867188A1 (enExample)
WO (1) WO2013138795A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021158073A1 (ko) * 2020-02-06 2021-08-12 아주대학교산학협력단 항원 유래 t 세포 항원 에피토프 또는 이를 포함하는 펩타이드를 세포 표면에 제시하기 위한 융합항체, 및 이를 포함하는 조성물
JP2023524733A (ja) * 2020-05-04 2023-06-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子発現を活性化及びサイレンシングするためのエフェクタードメインの作出、同定及び性質決定のための組成物、システム及び方法
JP2023534800A (ja) * 2020-07-13 2023-08-14 ナショナル ユニヴァーシティー オブ シンガポール ウイルスワクチンおよび腫瘍ワクチンの開発、がん免疫療法、ならびに自己免疫疾患の診断および治療における治療用途のためのペプチド性アジュバント

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX
WO2015069587A2 (en) 2013-11-06 2015-05-14 Merck Sharp & Dohme Corp. Peptide containing conjugates for dual molecular delivery of oligonucleotides
CN113105559A (zh) * 2013-12-12 2021-07-13 生命技术公司 增强转染的膜穿透性肽和组合物以及其使用方法
EP3094348B1 (en) 2014-01-14 2025-03-05 AbVacc, Inc. Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
WO2015121457A1 (en) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US10507228B2 (en) * 2015-04-20 2019-12-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and compositions related to KRAS inhibitors
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US9957325B2 (en) * 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017120213A1 (en) * 2016-01-05 2017-07-13 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
WO2017132235A1 (en) * 2016-01-26 2017-08-03 Dana-Farber Cancer Institute, Inc. METHODS FOR TREATING BRAIN METASTASES USING COMBINATIONS OF ANTI-P13K AND ANTI-mTOR AGENTS
CN105837665B (zh) * 2016-05-16 2019-04-30 江苏大学 特异性抑制hb-egf促肿瘤细胞迁移浸润的多肽
US9611297B1 (en) 2016-08-26 2017-04-04 Thrasos Therapeutics Inc. Compositions and methods for the treatment of cast nephropathy and related conditions
WO2018053463A1 (en) 2016-09-19 2018-03-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2017375828B2 (en) * 2016-12-16 2021-04-15 Avixgen Inc Cytoplasmic transduction peptide and intracellular messenger comprising same
WO2018111051A1 (ko) * 2016-12-16 2018-06-21 (주)에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
US12077590B2 (en) 2017-02-22 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
EP3790571B1 (en) * 2018-05-03 2024-08-14 University Of Utah Research Foundation Peptides derived from oca-b for use in the treatment of autoimmune diseases and of leukemia
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
EP3808840A4 (en) * 2018-06-14 2022-03-23 Avixgen Inc. Pharmaceutical composition comprising fusion protein of cell-penetrating peptide and rpe65 for treatment of leber's congenital amaurosis
JP7113918B2 (ja) * 2018-06-14 2022-08-05 アヴィックスジェン・インコーポレイテッド 細胞透過ペプチドと結合した融合タンパク質、および融合タンパク質または細胞透過ペプチドと上皮細胞成長因子を有効成分として含む組成物
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
US12643944B2 (en) 2019-11-12 2026-06-02 Iprogen Biotech Inc. Antibody-payload conjugates with enhanced delivery domain and uses thereof
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases
CN117736338A (zh) * 2023-12-08 2024-03-22 温州医科大学 一种角质细胞生长因子-透皮肽融合蛋白及其制备与应用
EP4711380A1 (en) * 2024-09-16 2026-03-18 Fundació Institut Hospital del Mar d'Investigacions Mèdiques Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
WO2026087627A1 (en) * 2024-10-22 2026-04-30 Ospedale San Raffaele S.R.L. Fusion protein
KR102996327B1 (ko) 2025-11-03 2026-07-28 주식회사 코씨드바이오팜 베타 디펜신2 유래 세포 투과능을 개선한 개량형 신규 거대분자 전송 도메인 개발 및 이를 이용한 피부 생리 활성 분자의 경피 전달 시스템

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743422B1 (en) * 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU5440800A (en) * 1999-05-21 2000-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 10
EE200200531A (et) * 2002-09-17 2004-04-15 O� InBio Terapeutiliste rakkusisenevate antikehade saamineja kasutamine
AU2010238346A1 (en) * 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
WO2010129023A2 (en) * 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
EP2928915A4 (en) * 2012-12-07 2016-07-27 Permeon Biolog Inc FGF-10 COMPLEX

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021158073A1 (ko) * 2020-02-06 2021-08-12 아주대학교산학협력단 항원 유래 t 세포 항원 에피토프 또는 이를 포함하는 펩타이드를 세포 표면에 제시하기 위한 융합항체, 및 이를 포함하는 조성물
US12590156B2 (en) 2020-02-06 2026-03-31 Ajou University Industry-Academic Cooperation Foundation Fusion antibody for presenting antigen-derived T cell antigen epitope or peptide containing same on cell surface, and composition comprising same
JP2023524733A (ja) * 2020-05-04 2023-06-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子発現を活性化及びサイレンシングするためのエフェクタードメインの作出、同定及び性質決定のための組成物、システム及び方法
JP7869753B2 (ja) 2020-05-04 2026-06-03 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子発現を活性化及びサイレンシングするためのエフェクタードメインの作出、同定及び性質決定のための組成物、システム及び方法
JP2023534800A (ja) * 2020-07-13 2023-08-14 ナショナル ユニヴァーシティー オブ シンガポール ウイルスワクチンおよび腫瘍ワクチンの開発、がん免疫療法、ならびに自己免疫疾患の診断および治療における治療用途のためのペプチド性アジュバント

Also Published As

Publication number Publication date
AU2013231851A1 (en) 2014-09-11
CA2867188A1 (en) 2013-09-19
EP2825561A4 (en) 2016-03-09
WO2013138795A1 (en) 2013-09-19
US20150266939A1 (en) 2015-09-24
EP2825561A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
US20150266939A1 (en) Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
CN112409483B (zh) 抗pd-l1纳米抗体
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
US8404233B2 (en) Neutralizing monoclonal antibody against human DLL4
KR101151805B1 (ko) 바이포달 펩타이드 바인더
DK2814842T3 (en) ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1
CN103003306B (zh) 抗体
AU2005216126B2 (en) Binding peptidomimetics and uses of the same
EP1351987A2 (en) Hybrid antibodies
JP2021533203A (ja) Ｃｄ１３７とｐｄ−ｌ１に特異的な新規融合タンパク質
CN106957365B (zh) 一种单克隆抗体FnAb8及其应用
CN115461358A (zh) 一种细胞穿膜肽及其应用
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
US20140271640A1 (en) FGF-10 Complexes
US20150307576A1 (en) Fgf-10 complexes
CN113227127A (zh) 向胃肠系统递送酬载的btnl3/8导引构建体
US20240417452A1 (en) Anti-mesothelin nanobodies and use thereof
US20240190934A1 (en) Engineered interleukin-10 and fusion proteins thereof
KR20210091220A (ko) 부착된 세포에 직접 신호를 보내지 않는 비-천연 nkg2d 수용체
WO2019109954A1 (zh) PD-1-Fc融合蛋白及其制备方法和用途
CN111378040B (zh) 检测多种恶性肿瘤细胞的抗体及其应用
CN106957364B (zh) 一种单克隆抗体FnAb12及其应用
US20150030593A1 (en) Compositions of penetration-enhanced targeting proteins and methods of use
CN119613545B (zh) 非天然氨基酸修饰的抗ccl5纳米抗体
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170912